Structured evidence table for Ergothioneine Blood Pressure Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Ergothioneine Blood Pressure Randomized Trial | Aim To investigate the association between serum ergothioneine and risk of developing dementia and its subtypes in a community-dwelling older population. | 4 | Meng X (2025) | Serum ergothioneine and risk of dementia in a general older Japanese population: the Hisayama Study. |
| Ergothioneine Blood Pressure Randomized Trial | Cox proportional hazards models were used to estimate the hazard ratios (HRs) and their 95% confidence intervals for the association between serum ergothioneine levels and the risk of dementia subtypes. | 4 | Meng X (2025) | Serum ergothioneine and risk of dementia in a general older Japanese population: the Hisayama Study. |
| Ergothioneine Blood Pressure Randomized Trial | The age- and sex-adjusted HRs for all-cause dementia, AD, and non-AD dementia decreased progressively across increasing quartiles of serum ergothioneine (all P for trend Conclusions Our findings showed that higher serum ergothioneine levels were associated with a lower risk of developing all-cause dementia, AD, and non-AD dementia in an older Japanese population. | 4 | Meng X (2025) | Serum ergothioneine and risk of dementia in a general older Japanese population: the Hisayama Study. |
| Ergothioneine Blood Pressure Randomized Trial | Methods In this prospective longitudinal analysis of participants enrolled in the Hisayama Study, 1344 Japanese community-residents aged 65 years and over without dementia at baseline were followed prospectively for a median of 11.2 years (2012-2023). | 4 | Meng X (2025) | Serum ergothioneine and risk of dementia in a general older Japanese population: the Hisayama Study. |
| Ergothioneine Blood Pressure Randomized Trial | This is particularly important for at-risk populations such as Apolipoprotein E () ε4 allele carriers (), those with a family history of dementia (), and those at an early stage of cognitive decline, known as Subjective Cognitive Decline (SCD) (). | 4 | Shan Jiatong (2025) | Study protocol: The efficacy of mushroom to prevent cognitive decline in at-risk middle-aged adults and young-olds living in the community |
| Ergothioneine Blood Pressure Randomized Trial | Without early intervention, these at-risk populations groups are likely to progress to dementia. | 4 | Shan Jiatong (2025) | Study protocol: The efficacy of mushroom to prevent cognitive decline in at-risk middle-aged adults and young-olds living in the community |
| Ergothioneine Blood Pressure Randomized Trial | For example, the latest approved antibody intravenous (IV) infusion therapy, Lecanemab, only showed a moderately lesser decline in measures of cognition and function than placebo and it was associated with adverse events (). | 4 | Shan Jiatong (2025) | Study protocol: The efficacy of mushroom to prevent cognitive decline in at-risk middle-aged adults and young-olds living in the community |
| Ergothioneine Blood Pressure Randomized Trial | Mitchell et al., 2023 Murman, 2015 Subramaniam et al., 2015 Cognitive declines can begin in one’s 30s, particularly affecting the ability to process new information and solve problems, though most people become aware of the decline in their 40s(;). | 4 | Shan Jiatong (2025) | Study protocol: The efficacy of mushroom to prevent cognitive decline in at-risk middle-aged adults and young-olds living in the community |
Source documents